[Skip to Navigation]
Comment & Response
July 2017

Could Albumin Be a Biomarker to Monitor the Effect of Intravenous Immunoglobulin on Guillain-Barré Syndrome?

Author Affiliations
  • 1Neuroscience Center, Department of Neurology, the First Hospital of Jilin University, Changchun, China
  • 2Department of Life Sciences, National Natural Science Foundation of China, Beijing, China
JAMA Neurol. 2017;74(7):871-872. doi:10.1001/jamaneurol.2017.0563

To the Editor Fokkink and colleagues1 reported that hypoalbuminemia was associated with a severe clinical course and poor outcomes among patients with Guillain-Barré syndrome (GBS) who received intravenous immunoglobulin treatment. They proposed that the serum albumin could be a potential biomarker to monitor the treatment responses to intravenous immunoglobulin among patients with GBS.1 However, we have several concerns about the study.

Add or change institution